OBiO Tech
Weiran Shen is currently the Vice President R&D at OBiO Technology, and serves as a Board Member at LEAP Initiative and Committee Member at Neusparks community. Prior to these roles, Weiran was at Kriya Therapeutics as an Associate Director & Director and at Sangamo Therapeutics, Inc. as a Scientist II project leader. Weiran also has experience as a Project Leader at the University of Pennsylvania. Weiran holds a Postgraduate Degree from the University of Pennsylvania and a Doctor of Philosophy - PhD from the University of Kansas Medical Center.
This person is not in any offices
OBiO Tech
OBiO Technology is a gene and cell therapy CRO and CDMO founded. We offer holistic research, development, and manufacturing solutions for vectorology studies, functional genomics, process and analytical development, IND-enabling CMC, clinical and commercial manufacturing. With "enable gene therapy for better lives" as our mission, we are committed to providing high-quality service to global customers, advancing your product from bench to clinic, and bringing benefit to populations around the world. We are committed to provide high quality CDMO service for preclinical, IND, clinical and commercial stages consumers worldwide. Plasmids, mRNA AAV, LVV, Ad viral vector, Cell therapy manufacturing, CAR-T, NK, Treg... Oncolytic virus Technologies Inducible viral vector packaging Ultralow endotoxin process AAVneO for AAV variants with tissue specific tropism For business inquiries, please contact bd@obiosh.com. More information and job openings at: www.obio-tech.com.